Abstract:Introduction: Targeting CD19, a significant surface marker of B cell malignant cells, with anti-CD19/CD3 bispecific antibodies became new choices in B cell hematological malignancies. Blinatumomab as the first generation CD19/CD3 bispecific antibody (bsAb) was approved for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia. However, it also has its own limitations, including side effects and limited efficacy. Bruton tyrosine kinase (BTK) inhibitor, ibrutinib has been shown to inhibit the IL-2-induced tyrosine kinase (ITK) which expressed in T and NK cells. This inhibition could result in modulation of cytokine production by T cells. Here we reported a newly designed CD19/CD3 bispecific antibody (A-319) with similar mechanism of action as blinatumomab. To further improve the efficacy and reduce side effects, we tried to combine ibrutinib with A-319, and explore the biological effects and the mechanisms of enhanced efficacy and reduced CRS in vitro and in vivo. Methods: A-319 was provided by ITabMed Ltd (Shanghai, China). CFSE was used to evaluate the proliferation of T cells, and CD25/CD69 staining was applied to assess the activation of T cells induced by A-319. Supernatant from co-cultured tumor and T cells was collected and measured for lactate dehydrogenase (LDH) lysis to measure cytotoxicity. Humanized mice model were built by human PBMC injection into NOG mice. To build CRS model, we allowed Raji derived tumor to grow up to 600-800mm3, at which point we dosed mice with high dose A-319(20μg/kg). Tube formation assay using HUVEC cells was performed to explore the effects of ibrutinib on angiogenesis. Results: A-319 effectively induced CD19-positive tumor cell lysis. The regression analysis presented a significant correlation between CD19 expression of target cells and the sensitivity to A-319 (p < 0.01). Exposure T cells to A-319 enhanced T cell proliferation and promoted T cell activation (CD25+CD69+T cells) significantly. Moreover, A-319 produced remarkable anti-tumor effects in vivo though companied by CRS. Interestingly, the addition of ibrutinib inhibited A-319 induced CRS and improve the anti-tumor efficacy in vitro and in vivo. Experiments exploring the mechanisms of the combined effects showed that ibrutinib could inhibit the infiltration of M2 (CD163, Arg-1) macrophage and normalize vascular (CD34+α-SMA+) in vivo compared with A-319. The in vitro results also presented that ibrutinib could polarize macrophage into M1 (CD80, CD86, iNOS). Tube formation assay on HUVEC cells proved that ibrutinib could inhibit macrophage mediated tube formation. Keywords: Tumor Biology and Heterogeneity, Combination Therapies, Immunotherapy No conflicts of interests pertinent to the abstract.

The Impact of Basiliximab on Clinical Treg Detection Through the Interference with CD25 Binding Site.

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

Impact of Basiliximab on the Proportion of Regulatory T Cells and Their Subsets Early after Renal Transplantation: a Preliminary Report.

Bruton's Tyrosine Kinase Ablation Inhibits B Cell Responses and Antibody Production for the Prevention of Chronic Rejection in Cardiac Transplantation.

The Effect of CD3-specific Monoclonal Antibody on Treating Experimental Autoimmune Myasthenia Gravis.

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

[Effects of Humanized Recombinant CD25 Monoclonal Antibody on Activation and Proliferation of T Lymphocytes].

Blockade of BLyS inhibits B cell responses and antibody production for the prevention of chronic transplant rejection

Safety assessment of basiliximab using real-world adverse event data from the FDA Adverse Event Reporting System Database: A retrospective observational study

Assessment Of Re-188 Marked Anti Mhc Class Ii Antibody By Peripheral Blood Mononuclear Cells Stimulated By Donor Alloantigen

Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer

Helper T Cell (CD4 + ) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Basiliximab for the Treatment of Steroid-Refractory Acute Graft-Versus-host Disease after Unmanipulated HLA-mismatched/haploidentical Hematopoietic Stem Cell Transplantation.

TGF-β–Induced Regulatory T Cells Directly Suppress B Cell Responses Through a Noncytotoxic Mechanism

A CD25×TIGIT bispecific antibody induces anti-tumor activity through selective intratumoral Treg cell depletion

I-124 Radiolabeled Basiliximab for CD25-Targeted Immuno-PET Imaging of Activated T Cells

Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping

[The Identical Effects of B7-1 and B7-2 on Regulation of Human IL-2 Gene Transcription Factors NF-kappa B and AP-1].

The Influence of Cyclosporin A on Lymphocyte Attenuator Expression

THE CD19/CD3 BISPECIFIC ANTIBODY WORK EFFECTIVELY AS ADJUNCT WITH IBRUTINIB ON THE TREATMENT OF B‐CELL LYMPHOMA

Non‐IL‐2‐blocking anti‐CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic effects with anti‐CTLA‐4 therapy